Is it now time to prepare psychiatry for a psychedelic future?

David Nutt & colleagues, writing in the British Journal of Psychiatry, write: "Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these communities might respond to these developments."

For more psychedelic news and research, visit the psychedelic health professional network homepage.